Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Transmedics Group Inc (NQ: TMDX )

84.94 -0.56 (-0.65%)
Streaming Delayed Price Updated: 11:28 AM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Transmedics Group Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Looking Into TransMedics Gr's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning TransMedics Gr Stock In The Last 5 Years
Via Benzinga
Expert Ratings For TransMedics Gr
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,600 Today
Via Benzinga
(TMDX) - Analyzing TransMedics Gr's Short Interest
Via Benzinga
Why Shares of TransMedics Stock Plunged This Week
TransMedics' revolutionary Organ Care System, high sales growth, and newfound profitability combine with its towering valuation to create wild volatility. 
Via The Motley Fool
$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 Today
Via Benzinga
Navigating 10 Analyst Ratings For TransMedics Gr
Via Benzinga
Peering Into TransMedics Gr's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning TransMedics Gr Stock In The Last 5 Years
Via Benzinga
TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside
Needham initiated coverage on TransMedics, highlighting its Organ Care System technology and National OCS Program, which are revolutionizing organ transplants with strong revenue growth, projected... 
Via Benzinga
RxSight Stock Sees Relative Strength Rating Rise To 91
On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91. 
Via Investor's Business Daily
1 No-Brainer Growth Stock I Can't Wait to Buy Again if the Market Crashes
A long lead in a niche industry ripe for disruption could make this stock a top performer. 
Via The Motley Fool
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why TransMedics Group Stock Is Soaring Today
This medical technology disruptor continues to impress investors. 
Via The Motley Fool
Assessing TransMedics Gr: Insights From 6 Financial Analysts
Via Benzinga
$1000 Invested In TransMedics Gr 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $100 Invested In TransMedics Gr 5 Years Ago Would Be Worth Today
Via Benzinga
Q3’s Rising Stars: 3 Growth Stocks for Your Must-Watch List
These growth stocks to watch exceeded analyst expectations in recent quarterly results and have ample opportunities to expand. 
Via InvestorPlace
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
TMDX Stock Earnings: TransMedics Gr Beats EPS, Beats Revenue for Q2 2024
TMDX stock results show that TransMedics Gr beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The Analyst Landscape: 9 Takes On TransMedics Gr
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
How Is The Market Feeling About TransMedics Gr?
Via Benzinga
3 Breakthrough Medical Device Stocks to Invest In Now
Uncover the potential of leading medical device stocks boasting solid fundamentals and a promising future ahead. 
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
These healthcare stocks have clear paths to growth over the next few years. 
Via The Motley Fool
Critical Insights From TransMedics Gr Analyst Ratings: What You Need To Know
Via Benzinga
The 3 Best Medical Device Stocks to Buy in June 2024
Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy. 
Via InvestorPlace
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Via Benzinga
This MedTech Company Has Market Expansion Opportunity, Says Bullish Analyst
Strong data from TransMedics' clinical trials is expected to drive adoption. Longer-term, the annual market opportunity is $1.5 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.